HEARTCARE-B (06609) announces a joyful profit forecast, expecting the adjusted net profit for the first half of the year to be no less than 70 million yuan, an increase of at least 104.7% year-on-year.

Heartcare-B (06609) announced that the group is expected to achieve revenue of no less than 280 million yuan in the first half of 2026, an increase of at least 50.9% compared to the previous year; net profit is expected to be no less than 60 million yuan, with net profit in the same period of 2025 being 50.9 million yuan; adjusted net profit is expected to be no less than 70 million yuan, an increase of at least 104.7% compared to the previous year. The announcement stated that the expected performance growth is mainly due to: revenue growth is attributed to the wider recognition of the group's products among the customer base, leading to continued growth in end-user demand; the group's business coverage in hospitals has further expanded during the reporting period; and rapid revenue growth in the three core businesses (ischemic stroke, hemorrhagic stroke, and vascular occlusion). The increase in adjusted net profit is mainly due to the higher revenue contribution from high-margin products, resulting in an overall increase in gross profit margin compared to the same period last year; and improved operational efficiency, with effective control over sales and distribution expenses and administrative expenses.